WAVE Life Sciences, a preclinical biotech developing optimized RNA
therapies for rare diseases, raised $102 million by offering 6.4 million
shares at $16, the midpoint of the range of $15 to $17. The company
originally planned to offer 5.0 million shares. Existing investors and
Teva plan to buy $62 million on the IPO (61% of the deal). WAVE Life
Sciences plans to list on the Nasdaq under the symbol WVE. Jefferies and Leerink Partners acted as lead managers on the deal.
This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.
Blogger Comment
Facebook Comment